Summary

The global Virtual Drug Discovery Service market is projected to grow from US$ 1002 million in 2025 to US$ 2161 million by 2032, at a CAGR of 11.6% (2026-2032), driven by critical product segments and diverse end‑use applications.
Virtual Drug Discovery Service refers to third-party scientific research services that apply computational chemistry, molecular modeling, structural bioinformatics, cheminformatics, artificial intelligence, machine learning and physics-based simulation to support pharmaceutical and biotechnology drug discovery programs. The market focuses on scientific execution delivered to external clients through project-based fee-for-service, dedicated FTE teams, platform-assisted scientific services or integrated discovery collaborations. Typical workflows cover target assessment, protein structure modeling, binding-site analysis, virtual screening, molecular docking, pharmacophore modeling, structure-based and ligand-based drug design, QSAR, molecular dynamics, free-energy calculations, AI-enabled molecular generation, property and ADMET prediction, hit identification, hit-to-lead and lead optimization. Virtual Drug Discovery Service increasingly operates within iterative design-make-test-analyze cycles, where computational predictions guide compound prioritization and experimental results are fed back into subsequent modeling and molecular design. The research scope centers on commercially delivered computational and in silico scientific services in which the provider performs substantive modeling, screening, prediction or molecular design work for external drug discovery customers. Major CRO service frameworks demonstrate that CADD is now used from hit identification through lead optimization and may be delivered either independently or within integrated discovery programs.
Key Findings
North America and Europe remain the deepest commercial supply centers for Virtual Drug Discovery Service
Small molecule discovery remains the most commercially mature application area for computational services
Project based FFS and dedicated FTE remain mainstream commercial delivery models
AI and physics based workflows are shifting demand toward integrated drug discovery services
Market Trends
Virtual Drug Discovery Service is moving from isolated computational tasks toward continuous involvement in drug discovery decision-making. Traditional docking, pharmacophore modeling and QSAR remain important, but customers increasingly expect suppliers to combine these methods with molecular dynamics, free-energy calculations, large-scale virtual screening, protein structure modeling, generative AI and multiparameter molecular optimization. The most important change is the integration of computational scientists with medicinal chemistry, structural biology, assays and DMPK within iterative design-make-test-analyze workflows. This shifts customer purchasing criteria away from access to individual algorithms and toward the probability of generating experimentally actionable molecules. AI-native workflows are also becoming more closely combined with physics-based approaches rather than replacing them outright, particularly where binding affinity, selectivity and molecular property optimization require interpretable scientific evidence. At the same time, routine docking and standardized prediction tasks are becoming easier to internalize, placing greater competitive value on complex modeling, proprietary data, experienced drug-design scientists and experimentally validated closed-loop discovery capabilities.
Market Dynamics
Drivers
Growth in Virtual Drug Discovery Service is supported by pharmaceutical and biotechnology companies seeking to improve early discovery productivity while controlling the cost and time associated with synthesis and experimental screening. Increasing chemical-space complexity, the expansion of virtual and asset-centric biotechnology companies, and broader use of external discovery teams are creating sustained demand for specialized computational expertise that is difficult to maintain internally. Improvements in structural prediction, GPU and cloud computing, molecular simulation, AI-generated molecular design and predictive modeling are also expanding the range of drug discovery decisions that can be supported computationally. In particular, the ability to prioritize smaller numbers of higher-quality compounds for synthesis and testing increases the strategic value of computational services within integrated discovery programs.
Restraints
The market remains constrained by the variable predictive performance of computational models across targets, chemical series and therapeutic modalities. High-quality structural, biochemical and medicinal chemistry data remain critical inputs, and limited or inconsistent experimental datasets can materially reduce model reliability. Customers with large internal computational chemistry teams may also internalize routine virtual screening, docking and property-prediction work, creating pricing pressure on standardized services. In addition, advanced molecular simulations, free-energy calculations and large-scale AI models can require substantial computing resources and specialist personnel, while the economic value of these tools is ultimately dependent on experimental validation. These factors limit the extent to which computational workflows can be treated as universal substitutes for laboratory discovery.
Opportunities
The strongest opportunities are emerging in technically complex projects where computational methods can directly influence expensive experimental decisions. These include difficult or previously underexplored targets, large-scale chemical-space screening, free-energy-based lead optimization, AI-assisted multiparameter molecular design, targeted protein degradation, peptide and macrocycle design, and computational approaches that link target intelligence with molecule generation. Virtual and small biotechnology companies represent another attractive client group because they often rely on external scientific infrastructure rather than maintaining complete internal discovery organizations. The increasing combination of proprietary platforms with scientific project execution also creates an opportunity for providers to move from one-off modeling assignments toward longer-term discovery partnerships with higher customer retention and deeper participation in the drug development value chain.
Challenges
A central industry challenge is demonstrating that computational recommendations produce reproducible and experimentally useful results rather than attractive model-level performance alone. Suppliers must manage differences in data quality, target biology, assay systems and customer workflows while maintaining clear documentation and scientific interpretability. Regulatory expectations around AI are also becoming more structured. FDA and EMA good AI practice principles emphasize defined context of use, risk-based assessment, data governance, model performance evaluation, multidisciplinary expertise and lifecycle management, raising the importance of model credibility and traceability for providers whose outputs may influence regulated development decisions. Competition for experienced computational chemists, medicinal chemists, machine-learning scientists and structural biologists remains another constraint, while rapid technological change creates continual investment requirements in software, data and computing infrastructure.
Value Chain Analysis
The upstream value chain of Virtual Drug Discovery Service consists primarily of scientific data, structural biology information, chemical libraries, proprietary and public molecular datasets, computational software, AI models, cloud and high-performance computing resources, and specialist scientific talent. Unlike manufacturing industries, the principal inputs are intellectual property, data quality, computational infrastructure and multidisciplinary expertise rather than physical raw materials. Providers that own proprietary models or accumulated experimental datasets can generate additional value by improving prediction accuracy and shortening the iteration between computational design and laboratory testing.
The midstream layer comprises integrated discovery CROs, specialist computational chemistry firms, AI-native drug discovery platforms and smaller boutique scientific service providers. Their value is created through target and molecular analysis, hypothesis generation, compound prioritization and optimization, and increasingly through coordination with medicinal chemistry and experimental validation. Downstream customers include large pharmaceutical companies, small and mid-sized biotechnology companies, virtual or asset-centric biotechs and translational research organizations. The highest-value service models are increasingly those that influence multiple successive discovery decisions rather than delivering a single computational output, because deeper participation in the DMTA cycle improves customer retention and makes scientific performance more important than simple labor-cost arbitrage.
Segment Insights
By workflow stage, hit identification, hit-to-lead and lead optimization represent the most established commercial areas because computational recommendations can be directly connected to compound selection, synthesis priorities and structure-activity relationship decisions. Target identification and computational biology are becoming more important as AI and multimodal biological data expand the upstream scope of Virtual Drug Discovery Service. From a technology perspective, structure-based drug design and ligand-based drug design continue to form the commercial foundation, while molecular simulation, free-energy methods and AI/ML-driven molecular design are gaining strategic importance in higher-value projects.
Small molecules remain the most mature modality because structural modeling, medicinal chemistry and property-optimization workflows are well established and supported by large historical datasets. Opportunities are nevertheless broadening toward peptides, macrocycles, therapeutic proteins, targeted protein degradation and selected nucleic-acid programs as computational approaches become more modality-specific. From a delivery-model perspective, project-based fee-for-service remains important for defined tasks, while dedicated FTE and integrated discovery models are better suited to programs requiring continuous iteration. Platform-assisted scientific services are emerging between software licensing and conventional CRO delivery, combining proprietary computational technology with scientists who execute and interpret projects for customers.
Downstream Market Opportunities
The strongest downstream demand comes from pharmaceutical and biotechnology companies seeking to increase the productivity of early discovery portfolios without proportionally expanding internal research infrastructure. Large pharmaceutical customers tend to require highly specialized modeling, overflow capacity and integration with existing medicinal chemistry teams, while small and mid-sized biotechnology companies often outsource a larger share of discovery execution. Virtual and asset-centric biotech represents a particularly favorable opportunity because these companies typically maintain lean internal organizations and rely on external partners for computational chemistry, medicinal chemistry and experimental validation. Demand is also expanding where computational services can address difficult targets, reduce experimental screening requirements or support rapid portfolio decisions across multiple molecular series.
Regional Insights
North America and Europe remain the most developed commercial markets for Virtual Drug Discovery Service, supported by dense pharmaceutical and biotechnology ecosystems, established computational chemistry expertise and a large base of specialist discovery CROs. Europe, particularly the United Kingdom and several continental European research clusters, has a notable concentration of boutique computational chemistry providers alongside integrated drug discovery organizations. North America combines major CRO platforms, computational software-and-service companies and AI-native discovery businesses, creating one of the broadest ranges of service models globally.
Asia is becoming increasingly important but remains structurally diverse. India has developed a strong position in integrated discovery outsourcing and FTE-based computational chemistry, benefiting from established medicinal chemistry and CRO infrastructure. China combines large discovery CRO organizations with rapidly expanding AI-for-Science and AI-enabled molecular design capabilities, creating increasing competition in integrated dry-lab and wet-lab discovery. Japan and South Korea have active AI drug discovery ecosystems but fewer independent commercial computational CROs, while Taiwan and Southeast Asia currently have smaller pools of dedicated service providers. The regional competitive advantage is therefore shifting from labor cost alone toward scientific talent, proprietary technology, high-quality data, computing infrastructure and the speed with which computational recommendations can be experimentally validated.
Competitive Landscape Analysis
The competitive landscape of Virtual Drug Discovery Service is fragmented and multi-layered rather than dominated by a single supplier model. Large integrated discovery organizations such as WuXi AppTec, Pharmaron, Charles River, Evotec, IQVIA, Sygnature Discovery, Syngene and Aragen compete primarily through broad scientific coverage, multidisciplinary project teams and the ability to connect computational design directly with medicinal chemistry and experimental testing. Specialist providers such as Cresset, BioSolveIT, Molecular Forecaster and other focused computational chemistry companies compete through deeper expertise in selected modeling methods and complex discovery problems, while XtalPi, Schrödinger, DP Technology and other technology-oriented platforms emphasize combinations of AI, physics-based modeling and scalable computation. The distinction between CRO, software platform and AI drug discovery company is becoming less rigid as suppliers add scientific execution around proprietary technologies. Industry restructuring is also reinforcing this convergence: in 2026 IQVIA agreed to acquire selected Charles River European discovery assets, including five sites and a small-molecule AI platform, strengthening an end-to-end capability spanning target identification through lead optimization and early safety assessment. Competitive differentiation is consequently shifting toward integrated data, computational technology, experimental validation, scientific talent and the ability to generate repeatable project outcomes rather than software access or low-cost computational labor alone.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Virtual Drug Discovery Service market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
WuXi AppTec
Pharmaron
Charles River
Evotec
IQVIA
Sygnature Discovery
Syngene
Aragen
Jubilant Biosys
Sai Life Sciences
Aurigene Pharmaceutical Services
Viva Biotech
BioDuro
XtalPi
Schrödinger
TandemAI
Symeres
Cresset
Concept Life Sciences
Selvita
Domainex
Novalix
Oncodesign Services
ChemDiv
Simulations Plus
Charnwood Discovery
BioAscent
InSilico Medicine
DP Technology
Acellera
Excelra
Gfree Bio
Shanghai PharmaResources
FRONTEO
Segment by Type
Target Identification and Validation
Hit Identification and Virtual Screening
Hit-to-Lead
Lead Optimization
Others
Segment by Therapeutic Modality
Small Molecules
Peptides and Macrocycles
Antibodies and Therapeutic Proteins
Nucleic Acid Therapeutics
Others
Segment by Primary Computational Approach
Structure-Based Drug Design
Ligand-Based Drug Design
Molecular Simulation & Free-Energy Methods
ML-Driven Molecular Design & Screening
Others
Segment by Application
Large Pharmaceutical Companies
Small and Mid-sized Biotechnology Companies
Virtual and Asset-Centric Biotech
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Virtual Drug Discovery Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Virtual Drug Discovery Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Virtual Drug Discovery Service Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Target Identification and Validation
1.2.3 Hit Identification and Virtual Screening
1.2.4 Hit-to-Lead
1.2.5 Lead Optimization
1.2.6 Others
1.3 Market Segmentation by Therapeutic Modality
1.3.1 Global Virtual Drug Discovery Service Market Size by Therapeutic Modality, 2021 vs 2025 vs 2032
1.3.2 Small Molecules
1.3.3 Peptides and Macrocycles
1.3.4 Antibodies and Therapeutic Proteins
1.3.5 Nucleic Acid Therapeutics
1.3.6 Others
1.4 Market Segmentation by Primary Computational Approach
1.4.1 Global Virtual Drug Discovery Service Market Size by Primary Computational Approach, 2021 vs 2025 vs 2032
1.4.2 Structure-Based Drug Design
1.4.3 Ligand-Based Drug Design
1.4.4 Molecular Simulation & Free-Energy Methods
1.4.5 ML-Driven Molecular Design & Screening
1.4.6 Others
1.5 Market Segmentation by Application
1.5.1 Global Virtual Drug Discovery Service Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Large Pharmaceutical Companies
1.5.3 Small and Mid-sized Biotechnology Companies
1.5.4 Virtual and Asset-Centric Biotech
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Virtual Drug Discovery Service Revenue Estimates and Forecasts (2021-2032)
2.2 Global Virtual Drug Discovery Service Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Virtual Drug Discovery Service Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Virtual Drug Discovery Service Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Target Identification and Validation: Market Share by Key Players
3.3.2 Hit Identification and Virtual Screening: Market Share by Key Players
3.3.3 Hit-to-Lead: Market Share by Key Players
3.3.4 Lead Optimization: Market Share by Key Players
3.3.5 Others: Market Share by Key Players
3.4 Global Virtual Drug Discovery Service Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Virtual Drug Discovery Service Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Virtual Drug Discovery Service Market by Therapeutic Modality
4.2.1 Global Revenue by Therapeutic Modality (2021-2032)
4.2.2 Global Revenue-Based Market Share by Therapeutic Modality (2021-2032)
4.3 Global Virtual Drug Discovery Service Market by Primary Computational Approach
4.3.1 Global Revenue by Primary Computational Approach (2021-2032)
4.3.2 Global Revenue-Based Market Share by Primary Computational Approach (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Virtual Drug Discovery Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Virtual Drug Discovery Service Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Virtual Drug Discovery Service Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Virtual Drug Discovery Service Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Virtual Drug Discovery Service Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Virtual Drug Discovery Service Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Virtual Drug Discovery Service Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Virtual Drug Discovery Service Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Virtual Drug Discovery Service Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Virtual Drug Discovery Service Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Virtual Drug Discovery Service Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 WuXi AppTec
11.1.1 WuXi AppTec Corporation Information
11.1.2 WuXi AppTec Business Overview
11.1.3 WuXi AppTec Virtual Drug Discovery Service Product Features and Attributes
11.1.4 WuXi AppTec Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.1.5 WuXi AppTec Virtual Drug Discovery Service Revenue by Product in 2025
11.1.6 WuXi AppTec Virtual Drug Discovery Service Revenue by Application in 2025
11.1.7 WuXi AppTec Virtual Drug Discovery Service Revenue by Geographic Area in 2025
11.1.8 WuXi AppTec Virtual Drug Discovery Service SWOT Analysis
11.1.9 WuXi AppTec Recent Developments
11.2 Pharmaron
11.2.1 Pharmaron Corporation Information
11.2.2 Pharmaron Business Overview
11.2.3 Pharmaron Virtual Drug Discovery Service Product Features and Attributes
11.2.4 Pharmaron Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.2.5 Pharmaron Virtual Drug Discovery Service Revenue by Product in 2025
11.2.6 Pharmaron Virtual Drug Discovery Service Revenue by Application in 2025
11.2.7 Pharmaron Virtual Drug Discovery Service Revenue by Geographic Area in 2025
11.2.8 Pharmaron Virtual Drug Discovery Service SWOT Analysis
11.2.9 Pharmaron Recent Developments
11.3 Charles River
11.3.1 Charles River Corporation Information
11.3.2 Charles River Business Overview
11.3.3 Charles River Virtual Drug Discovery Service Product Features and Attributes
11.3.4 Charles River Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.3.5 Charles River Virtual Drug Discovery Service Revenue by Product in 2025
11.3.6 Charles River Virtual Drug Discovery Service Revenue by Application in 2025
11.3.7 Charles River Virtual Drug Discovery Service Revenue by Geographic Area in 2025
11.3.8 Charles River Virtual Drug Discovery Service SWOT Analysis
11.3.9 Charles River Recent Developments
11.4 Evotec
11.4.1 Evotec Corporation Information
11.4.2 Evotec Business Overview
11.4.3 Evotec Virtual Drug Discovery Service Product Features and Attributes
11.4.4 Evotec Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.4.5 Evotec Virtual Drug Discovery Service Revenue by Product in 2025
11.4.6 Evotec Virtual Drug Discovery Service Revenue by Application in 2025
11.4.7 Evotec Virtual Drug Discovery Service Revenue by Geographic Area in 2025
11.4.8 Evotec Virtual Drug Discovery Service SWOT Analysis
11.4.9 Evotec Recent Developments
11.5 IQVIA
11.5.1 IQVIA Corporation Information
11.5.2 IQVIA Business Overview
11.5.3 IQVIA Virtual Drug Discovery Service Product Features and Attributes
11.5.4 IQVIA Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.5.5 IQVIA Virtual Drug Discovery Service Revenue by Product in 2025
11.5.6 IQVIA Virtual Drug Discovery Service Revenue by Application in 2025
11.5.7 IQVIA Virtual Drug Discovery Service Revenue by Geographic Area in 2025
11.5.8 IQVIA Virtual Drug Discovery Service SWOT Analysis
11.5.9 IQVIA Recent Developments
11.6 Sygnature Discovery
11.6.1 Sygnature Discovery Corporation Information
11.6.2 Sygnature Discovery Business Overview
11.6.3 Sygnature Discovery Virtual Drug Discovery Service Product Features and Attributes
11.6.4 Sygnature Discovery Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.6.5 Sygnature Discovery Recent Developments
11.7 Syngene
11.7.1 Syngene Corporation Information
11.7.2 Syngene Business Overview
11.7.3 Syngene Virtual Drug Discovery Service Product Features and Attributes
11.7.4 Syngene Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.7.5 Syngene Recent Developments
11.8 Aragen
11.8.1 Aragen Corporation Information
11.8.2 Aragen Business Overview
11.8.3 Aragen Virtual Drug Discovery Service Product Features and Attributes
11.8.4 Aragen Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.8.5 Aragen Recent Developments
11.9 Jubilant Biosys
11.9.1 Jubilant Biosys Corporation Information
11.9.2 Jubilant Biosys Business Overview
11.9.3 Jubilant Biosys Virtual Drug Discovery Service Product Features and Attributes
11.9.4 Jubilant Biosys Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.9.5 Jubilant Biosys Recent Developments
11.10 Sai Life Sciences
11.10.1 Sai Life Sciences Corporation Information
11.10.2 Sai Life Sciences Business Overview
11.10.3 Sai Life Sciences Virtual Drug Discovery Service Product Features and Attributes
11.10.4 Sai Life Sciences Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Aurigene Pharmaceutical Services
11.11.1 Aurigene Pharmaceutical Services Corporation Information
11.11.2 Aurigene Pharmaceutical Services Business Overview
11.11.3 Aurigene Pharmaceutical Services Virtual Drug Discovery Service Product Features and Attributes
11.11.4 Aurigene Pharmaceutical Services Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.11.5 Aurigene Pharmaceutical Services Recent Developments
11.12 Viva Biotech
11.12.1 Viva Biotech Corporation Information
11.12.2 Viva Biotech Business Overview
11.12.3 Viva Biotech Virtual Drug Discovery Service Product Features and Attributes
11.12.4 Viva Biotech Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.12.5 Viva Biotech Recent Developments
11.13 BioDuro
11.13.1 BioDuro Corporation Information
11.13.2 BioDuro Business Overview
11.13.3 BioDuro Virtual Drug Discovery Service Product Features and Attributes
11.13.4 BioDuro Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.13.5 BioDuro Recent Developments
11.14 XtalPi
11.14.1 XtalPi Corporation Information
11.14.2 XtalPi Business Overview
11.14.3 XtalPi Virtual Drug Discovery Service Product Features and Attributes
11.14.4 XtalPi Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.14.5 XtalPi Recent Developments
11.15 Schrödinger
11.15.1 Schrödinger Corporation Information
11.15.2 Schrödinger Business Overview
11.15.3 Schrödinger Virtual Drug Discovery Service Product Features and Attributes
11.15.4 Schrödinger Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.15.5 Schrödinger Recent Developments
11.16 TandemAI
11.16.1 TandemAI Corporation Information
11.16.2 TandemAI Business Overview
11.16.3 TandemAI Virtual Drug Discovery Service Product Features and Attributes
11.16.4 TandemAI Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.16.5 TandemAI Recent Developments
11.17 Symeres
11.17.1 Symeres Corporation Information
11.17.2 Symeres Business Overview
11.17.3 Symeres Virtual Drug Discovery Service Product Features and Attributes
11.17.4 Symeres Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.17.5 Symeres Recent Developments
11.18 Cresset
11.18.1 Cresset Corporation Information
11.18.2 Cresset Business Overview
11.18.3 Cresset Virtual Drug Discovery Service Product Features and Attributes
11.18.4 Cresset Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.18.5 Cresset Recent Developments
11.19 Concept Life Sciences
11.19.1 Concept Life Sciences Corporation Information
11.19.2 Concept Life Sciences Business Overview
11.19.3 Concept Life Sciences Virtual Drug Discovery Service Product Features and Attributes
11.19.4 Concept Life Sciences Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.19.5 Concept Life Sciences Recent Developments
11.20 Selvita
11.20.1 Selvita Corporation Information
11.20.2 Selvita Business Overview
11.20.3 Selvita Virtual Drug Discovery Service Product Features and Attributes
11.20.4 Selvita Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.20.5 Selvita Recent Developments
11.21 Domainex
11.21.1 Domainex Corporation Information
11.21.2 Domainex Business Overview
11.21.3 Domainex Virtual Drug Discovery Service Product Features and Attributes
11.21.4 Domainex Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.21.5 Domainex Recent Developments
11.22 Novalix
11.22.1 Novalix Corporation Information
11.22.2 Novalix Business Overview
11.22.3 Novalix Virtual Drug Discovery Service Product Features and Attributes
11.22.4 Novalix Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.22.5 Novalix Recent Developments
11.23 Oncodesign Services
11.23.1 Oncodesign Services Corporation Information
11.23.2 Oncodesign Services Business Overview
11.23.3 Oncodesign Services Virtual Drug Discovery Service Product Features and Attributes
11.23.4 Oncodesign Services Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.23.5 Oncodesign Services Recent Developments
11.24 ChemDiv
11.24.1 ChemDiv Corporation Information
11.24.2 ChemDiv Business Overview
11.24.3 ChemDiv Virtual Drug Discovery Service Product Features and Attributes
11.24.4 ChemDiv Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.24.5 ChemDiv Recent Developments
11.25 Simulations Plus
11.25.1 Simulations Plus Corporation Information
11.25.2 Simulations Plus Business Overview
11.25.3 Simulations Plus Virtual Drug Discovery Service Product Features and Attributes
11.25.4 Simulations Plus Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.25.5 Simulations Plus Recent Developments
11.26 Charnwood Discovery
11.26.1 Charnwood Discovery Corporation Information
11.26.2 Charnwood Discovery Business Overview
11.26.3 Charnwood Discovery Virtual Drug Discovery Service Product Features and Attributes
11.26.4 Charnwood Discovery Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.26.5 Charnwood Discovery Recent Developments
11.27 BioAscent
11.27.1 BioAscent Corporation Information
11.27.2 BioAscent Business Overview
11.27.3 BioAscent Virtual Drug Discovery Service Product Features and Attributes
11.27.4 BioAscent Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.27.5 BioAscent Recent Developments
11.28 InSilico Medicine
11.28.1 InSilico Medicine Corporation Information
11.28.2 InSilico Medicine Business Overview
11.28.3 InSilico Medicine Virtual Drug Discovery Service Product Features and Attributes
11.28.4 InSilico Medicine Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.28.5 InSilico Medicine Recent Developments
11.29 DP Technology
11.29.1 DP Technology Corporation Information
11.29.2 DP Technology Business Overview
11.29.3 DP Technology Virtual Drug Discovery Service Product Features and Attributes
11.29.4 DP Technology Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.29.5 DP Technology Recent Developments
11.30 Acellera
11.30.1 Acellera Corporation Information
11.30.2 Acellera Business Overview
11.30.3 Acellera Virtual Drug Discovery Service Product Features and Attributes
11.30.4 Acellera Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.30.5 Acellera Recent Developments
11.31 Excelra
11.31.1 Excelra Corporation Information
11.31.2 Excelra Business Overview
11.31.3 Excelra Virtual Drug Discovery Service Product Features and Attributes
11.31.4 Excelra Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.31.5 Excelra Recent Developments
11.32 Gfree Bio
11.32.1 Gfree Bio Corporation Information
11.32.2 Gfree Bio Business Overview
11.32.3 Gfree Bio Virtual Drug Discovery Service Product Features and Attributes
11.32.4 Gfree Bio Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.32.5 Gfree Bio Recent Developments
11.33 Shanghai PharmaResources
11.33.1 Shanghai PharmaResources Corporation Information
11.33.2 Shanghai PharmaResources Business Overview
11.33.3 Shanghai PharmaResources Virtual Drug Discovery Service Product Features and Attributes
11.33.4 Shanghai PharmaResources Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.33.5 Shanghai PharmaResources Recent Developments
11.34 FRONTEO
11.34.1 FRONTEO Corporation Information
11.34.2 FRONTEO Business Overview
11.34.3 FRONTEO Virtual Drug Discovery Service Product Features and Attributes
11.34.4 FRONTEO Virtual Drug Discovery Service Revenue and Gross Margin (2021-2026)
11.34.5 FRONTEO Recent Developments

12 Virtual Drug Discovery Service Value Chain and Ecosystem Analysis
12.1 Virtual Drug Discovery Service Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Virtual Drug Discovery Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Virtual Drug Discovery Service Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Virtual Drug Discovery Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Virtual Drug Discovery Service Market Size Growth Rate by Therapeutic Modality, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Virtual Drug Discovery Service Market Size Growth Rate by Primary Computational Approach, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Virtual Drug Discovery Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Virtual Drug Discovery Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Virtual Drug Discovery Service Revenue by Region (US$ Million), 2021-2026
Table 7. Global Virtual Drug Discovery Service Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Virtual Drug Discovery Service Revenue by Players (US$ Million), 2021-2026
Table 10. Global Virtual Drug Discovery Service Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Virtual Drug Discovery Service Revenue, 2025
Table 13. Global Virtual Drug Discovery Service Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Virtual Drug Discovery Service Companies Headquarters
Table 15. Global Virtual Drug Discovery Service Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Virtual Drug Discovery Service Revenue by Type (US$ Million), 2021-2026
Table 19. Global Virtual Drug Discovery Service Revenue by Type (US$ Million), 2027-2032
Table 20. Global Virtual Drug Discovery Service Revenue by Therapeutic Modality (US$ Million), 2021-2026
Table 21. Global Virtual Drug Discovery Service Revenue by Therapeutic Modality (US$ Million), 2027-2032
Table 22. Global Virtual Drug Discovery Service Revenue by Primary Computational Approach (US$ Million), 2021-2026
Table 23. Global Virtual Drug Discovery Service Revenue by Primary Computational Approach (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Virtual Drug Discovery Service Revenue by Application (US$ Million), 2021-2026
Table 26. Global Virtual Drug Discovery Service Revenue by Application (US$ Million), 2027-2032
Table 27. Virtual Drug Discovery Service High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Virtual Drug Discovery Service Growth Accelerators and Market Barriers
Table 31. North America Virtual Drug Discovery Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Virtual Drug Discovery Service Growth Accelerators and Market Barriers
Table 33. Europe Virtual Drug Discovery Service Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Virtual Drug Discovery Service Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Virtual Drug Discovery Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Virtual Drug Discovery Service Investment Opportunities and Key Challenges
Table 37. Central and South America Virtual Drug Discovery Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Virtual Drug Discovery Service Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Virtual Drug Discovery Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. WuXi AppTec Corporation Information
Table 41. WuXi AppTec Description and Major Businesses
Table 42. WuXi AppTec Product Features and Attributes
Table 43. WuXi AppTec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. WuXi AppTec Revenue Proportion by Product in 2025
Table 45. WuXi AppTec Revenue Proportion by Application in 2025
Table 46. WuXi AppTec Revenue Proportion by Geographic Area in 2025
Table 47. WuXi AppTec Virtual Drug Discovery Service SWOT Analysis
Table 48. WuXi AppTec Recent Developments
Table 49. Pharmaron Corporation Information
Table 50. Pharmaron Description and Major Businesses
Table 51. Pharmaron Product Features and Attributes
Table 52. Pharmaron Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Pharmaron Revenue Proportion by Product in 2025
Table 54. Pharmaron Revenue Proportion by Application in 2025
Table 55. Pharmaron Revenue Proportion by Geographic Area in 2025
Table 56. Pharmaron Virtual Drug Discovery Service SWOT Analysis
Table 57. Pharmaron Recent Developments
Table 58. Charles River Corporation Information
Table 59. Charles River Description and Major Businesses
Table 60. Charles River Product Features and Attributes
Table 61. Charles River Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Charles River Revenue Proportion by Product in 2025
Table 63. Charles River Revenue Proportion by Application in 2025
Table 64. Charles River Revenue Proportion by Geographic Area in 2025
Table 65. Charles River Virtual Drug Discovery Service SWOT Analysis
Table 66. Charles River Recent Developments
Table 67. Evotec Corporation Information
Table 68. Evotec Description and Major Businesses
Table 69. Evotec Product Features and Attributes
Table 70. Evotec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Evotec Revenue Proportion by Product in 2025
Table 72. Evotec Revenue Proportion by Application in 2025
Table 73. Evotec Revenue Proportion by Geographic Area in 2025
Table 74. Evotec Virtual Drug Discovery Service SWOT Analysis
Table 75. Evotec Recent Developments
Table 76. IQVIA Corporation Information
Table 77. IQVIA Description and Major Businesses
Table 78. IQVIA Product Features and Attributes
Table 79. IQVIA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. IQVIA Revenue Proportion by Product in 2025
Table 81. IQVIA Revenue Proportion by Application in 2025
Table 82. IQVIA Revenue Proportion by Geographic Area in 2025
Table 83. IQVIA Virtual Drug Discovery Service SWOT Analysis
Table 84. IQVIA Recent Developments
Table 85. Sygnature Discovery Corporation Information
Table 86. Sygnature Discovery Description and Major Businesses
Table 87. Sygnature Discovery Product Features and Attributes
Table 88. Sygnature Discovery Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Sygnature Discovery Recent Developments
Table 90. Syngene Corporation Information
Table 91. Syngene Description and Major Businesses
Table 92. Syngene Product Features and Attributes
Table 93. Syngene Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Syngene Recent Developments
Table 95. Aragen Corporation Information
Table 96. Aragen Description and Major Businesses
Table 97. Aragen Product Features and Attributes
Table 98. Aragen Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Aragen Recent Developments
Table 100. Jubilant Biosys Corporation Information
Table 101. Jubilant Biosys Description and Major Businesses
Table 102. Jubilant Biosys Product Features and Attributes
Table 103. Jubilant Biosys Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Jubilant Biosys Recent Developments
Table 105. Sai Life Sciences Corporation Information
Table 106. Sai Life Sciences Description and Major Businesses
Table 107. Sai Life Sciences Product Features and Attributes
Table 108. Sai Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Sai Life Sciences Recent Developments
Table 110. Aurigene Pharmaceutical Services Corporation Information
Table 111. Aurigene Pharmaceutical Services Description and Major Businesses
Table 112. Aurigene Pharmaceutical Services Product Features and Attributes
Table 113. Aurigene Pharmaceutical Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Aurigene Pharmaceutical Services Recent Developments
Table 115. Viva Biotech Corporation Information
Table 116. Viva Biotech Description and Major Businesses
Table 117. Viva Biotech Product Features and Attributes
Table 118. Viva Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Viva Biotech Recent Developments
Table 120. BioDuro Corporation Information
Table 121. BioDuro Description and Major Businesses
Table 122. BioDuro Product Features and Attributes
Table 123. BioDuro Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. BioDuro Recent Developments
Table 125. XtalPi Corporation Information
Table 126. XtalPi Description and Major Businesses
Table 127. XtalPi Product Features and Attributes
Table 128. XtalPi Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. XtalPi Recent Developments
Table 130. Schrödinger Corporation Information
Table 131. Schrödinger Description and Major Businesses
Table 132. Schrödinger Product Features and Attributes
Table 133. Schrödinger Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Schrödinger Recent Developments
Table 135. TandemAI Corporation Information
Table 136. TandemAI Description and Major Businesses
Table 137. TandemAI Product Features and Attributes
Table 138. TandemAI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. TandemAI Recent Developments
Table 140. Symeres Corporation Information
Table 141. Symeres Description and Major Businesses
Table 142. Symeres Product Features and Attributes
Table 143. Symeres Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Symeres Recent Developments
Table 145. Cresset Corporation Information
Table 146. Cresset Description and Major Businesses
Table 147. Cresset Product Features and Attributes
Table 148. Cresset Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Cresset Recent Developments
Table 150. Concept Life Sciences Corporation Information
Table 151. Concept Life Sciences Description and Major Businesses
Table 152. Concept Life Sciences Product Features and Attributes
Table 153. Concept Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Concept Life Sciences Recent Developments
Table 155. Selvita Corporation Information
Table 156. Selvita Description and Major Businesses
Table 157. Selvita Product Features and Attributes
Table 158. Selvita Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Selvita Recent Developments
Table 160. Domainex Corporation Information
Table 161. Domainex Description and Major Businesses
Table 162. Domainex Product Features and Attributes
Table 163. Domainex Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Domainex Recent Developments
Table 165. Novalix Corporation Information
Table 166. Novalix Description and Major Businesses
Table 167. Novalix Product Features and Attributes
Table 168. Novalix Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Novalix Recent Developments
Table 170. Oncodesign Services Corporation Information
Table 171. Oncodesign Services Description and Major Businesses
Table 172. Oncodesign Services Product Features and Attributes
Table 173. Oncodesign Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Oncodesign Services Recent Developments
Table 175. ChemDiv Corporation Information
Table 176. ChemDiv Description and Major Businesses
Table 177. ChemDiv Product Features and Attributes
Table 178. ChemDiv Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. ChemDiv Recent Developments
Table 180. Simulations Plus Corporation Information
Table 181. Simulations Plus Description and Major Businesses
Table 182. Simulations Plus Product Features and Attributes
Table 183. Simulations Plus Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Simulations Plus Recent Developments
Table 185. Charnwood Discovery Corporation Information
Table 186. Charnwood Discovery Description and Major Businesses
Table 187. Charnwood Discovery Product Features and Attributes
Table 188. Charnwood Discovery Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Charnwood Discovery Recent Developments
Table 190. BioAscent Corporation Information
Table 191. BioAscent Description and Major Businesses
Table 192. BioAscent Product Features and Attributes
Table 193. BioAscent Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. BioAscent Recent Developments
Table 195. InSilico Medicine Corporation Information
Table 196. InSilico Medicine Description and Major Businesses
Table 197. InSilico Medicine Product Features and Attributes
Table 198. InSilico Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. InSilico Medicine Recent Developments
Table 200. DP Technology Corporation Information
Table 201. DP Technology Description and Major Businesses
Table 202. DP Technology Product Features and Attributes
Table 203. DP Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. DP Technology Recent Developments
Table 205. Acellera Corporation Information
Table 206. Acellera Description and Major Businesses
Table 207. Acellera Product Features and Attributes
Table 208. Acellera Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Acellera Recent Developments
Table 210. Excelra Corporation Information
Table 211. Excelra Description and Major Businesses
Table 212. Excelra Product Features and Attributes
Table 213. Excelra Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Excelra Recent Developments
Table 215. Gfree Bio Corporation Information
Table 216. Gfree Bio Description and Major Businesses
Table 217. Gfree Bio Product Features and Attributes
Table 218. Gfree Bio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Gfree Bio Recent Developments
Table 220. Shanghai PharmaResources Corporation Information
Table 221. Shanghai PharmaResources Description and Major Businesses
Table 222. Shanghai PharmaResources Product Features and Attributes
Table 223. Shanghai PharmaResources Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. Shanghai PharmaResources Recent Developments
Table 225. FRONTEO Corporation Information
Table 226. FRONTEO Description and Major Businesses
Table 227. FRONTEO Product Features and Attributes
Table 228. FRONTEO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. FRONTEO Recent Developments
Table 230. Technologies, Platforms and Infrastructure
Table 231. Distributors List
Table 232. Market Trends and Market Evolution
Table 233. Market Drivers and Opportunities
Table 234. Market Challenges, Risks, and Restraints
Table 235. Research Programs/Design for This Report
Table 236. Key Data Information from Secondary Sources
Table 237. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Virtual Drug Discovery Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Target Identification and Validation Product Picture
Figure 3. Hit Identification and Virtual Screening Product Picture
Figure 4. Hit-to-Lead Product Picture
Figure 5. Lead Optimization Product Picture
Figure 6. Others Product Picture
Figure 7. Global Virtual Drug Discovery Service Market Size Growth Rate by Therapeutic Modality, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Small Molecules Product Picture
Figure 9. Peptides and Macrocycles Product Picture
Figure 10. Antibodies and Therapeutic Proteins Product Picture
Figure 11. Nucleic Acid Therapeutics Product Picture
Figure 12. Others Product Picture
Figure 13. Global Virtual Drug Discovery Service Market Size Growth Rate by Primary Computational Approach, 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Structure-Based Drug Design Product Picture
Figure 15. Ligand-Based Drug Design Product Picture
Figure 16. Molecular Simulation & Free-Energy Methods Product Picture
Figure 17. ML-Driven Molecular Design & Screening Product Picture
Figure 18. Others Product Picture
Figure 19. Global Virtual Drug Discovery Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Large Pharmaceutical Companies
Figure 21. Small and Mid-sized Biotechnology Companies
Figure 22. Virtual and Asset-Centric Biotech
Figure 23. Others
Figure 24. Virtual Drug Discovery Service Report Years Considered
Figure 25. Global Virtual Drug Discovery Service Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 27. Global Virtual Drug Discovery Service Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 28. Global Virtual Drug Discovery Service Revenue-Based Market Share by Region (2021-2032)
Figure 29. Global Virtual Drug Discovery Service Revenue-Based Market Share Ranking (2025)
Figure 30. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 31. Target Identification and Validation Revenue-Based Market Share by Player in 2025
Figure 32. Hit Identification and Virtual Screening Revenue-Based Market Share by Player in 2025
Figure 33. Hit-to-Lead Revenue-Based Market Share by Player in 2025
Figure 34. Lead Optimization Revenue-Based Market Share by Player in 2025
Figure 35. Others Revenue-Based Market Share by Player in 2025
Figure 36. Global Virtual Drug Discovery Service Revenue-Based Market Share by Type (2021-2032)
Figure 37. Global Virtual Drug Discovery Service Revenue-Based Market Share by Therapeutic Modality (2021-2032)
Figure 38. Global Virtual Drug Discovery Service Revenue-Based Market Share by Primary Computational Approach (2021-2032)
Figure 39. Global Virtual Drug Discovery Service Revenue-Based Market Share by Application (2021-2032)
Figure 40. North America Virtual Drug Discovery Service Revenue YoY (US$ Million), 2021-2032
Figure 41. North America Top 5 Players Virtual Drug Discovery Service Revenue (US$ Million) in 2025
Figure 42. North America Virtual Drug Discovery Service Revenue (US$ Million) by Application (2021-2032)
Figure 43. US Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 44. Canada Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 45. Mexico Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 46. Europe Virtual Drug Discovery Service Revenue YoY (US$ Million), 2021-2032
Figure 47. Europe Top 5 Players Virtual Drug Discovery Service Revenue (US$ Million) in 2025
Figure 48. Europe Virtual Drug Discovery Service Revenue (US$ Million) by Application (2021-2032)
Figure 49. Germany Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 50. France Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 51. U.K. Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 52. Italy Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 53. Russia Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 54. Asia-Pacific Virtual Drug Discovery Service Revenue YoY (US$ Million), 2021-2032
Figure 55. Asia-Pacific Top 8 Players Virtual Drug Discovery Service Revenue (US$ Million) in 2025
Figure 56. Asia-Pacific Virtual Drug Discovery Service Revenue (US$ Million) by Application (2021-2032)
Figure 57. Indonesia Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 58. Japan Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 59. South Korea Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 60. Australia Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 61. India Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 62. Indonesia Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 63. Vietnam Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 64. Malaysia Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 65. Philippines Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 66. Singapore Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 67. Central and South America Virtual Drug Discovery Service Revenue YoY (US$ Million), 2021-2032
Figure 68. Central and South America Top 5 Players Virtual Drug Discovery Service Revenue (US$ Million) in 2025
Figure 69. Central and South America Virtual Drug Discovery Service Revenue (US$ Million) by Application (2021-2032)
Figure 70. Brazil Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 71. Argentina Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 72. Middle East and Africa Virtual Drug Discovery Service Revenue YoY (US$ Million), 2021-2032
Figure 73. Middle East and Africa Top 5 Players Virtual Drug Discovery Service Revenue (US$ Million) in 2025
Figure 74. Middle East and Africa Virtual Drug Discovery Service Revenue (US$ Million) by Application (2021-2032)
Figure 75. GCC Countries Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 76. Israel Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 77. Egypt Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 78. South Africa Virtual Drug Discovery Service Revenue (US$ Million), 2021-2032
Figure 79. Virtual Drug Discovery Service Value Chain Mapping
Figure 80. Channels of Distribution (Direct Vs Distribution)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed